381 related articles for article (PubMed ID: 22494466)
61. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
[TBL] [Abstract][Full Text] [Related]
62. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
[TBL] [Abstract][Full Text] [Related]
63. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
Gerlach M; Double K; Reichmann H; Riederer P
J Neural Transm Suppl; 2003; (65):167-83. PubMed ID: 12946055
[TBL] [Abstract][Full Text] [Related]
64. [Pharmacological treatments of Parkinson's disease].
Nomoto M; Iwata S; Kaseda S
Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):111-22. PubMed ID: 11233302
[TBL] [Abstract][Full Text] [Related]
65. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
[TBL] [Abstract][Full Text] [Related]
66. Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson's disease therapeutics.
Moschovou K; Melagraki G; Mavromoustakos T; Zacharia LC; Afantitis A
Expert Opin Drug Discov; 2020 Jan; 15(1):53-62. PubMed ID: 31744341
[No Abstract] [Full Text] [Related]
67. Improving L-dopa therapy: the development of enzyme inhibitors.
Gershanik OS
Mov Disord; 2015 Jan; 30(1):103-13. PubMed ID: 25335824
[TBL] [Abstract][Full Text] [Related]
68. [Current Pharmacological Treatment for Parkinson's Disease].
Saitoh Y; Takahashi K
Brain Nerve; 2023 May; 75(5):441-449. PubMed ID: 37194511
[TBL] [Abstract][Full Text] [Related]
69. Modes of drug delivery used to manage Parkinson's disease.
Noble C
Nurs Times; 2006 Aug 8-14; 102(32):30-2. PubMed ID: 16922099
[TBL] [Abstract][Full Text] [Related]
70. Motor fluctuations in Parkinson's disease: pathophysiology and treatment.
Colosimo C; De Michele M
Eur J Neurol; 1999 Jan; 6(1):1-21. PubMed ID: 10209344
[TBL] [Abstract][Full Text] [Related]
71. Pharmacotherapy of Parkinson's disease: research from 1960 to 1991.
Pletscher A; DaPrada M
Acta Neurol Scand Suppl; 1993; 146():26-31. PubMed ID: 8101413
[TBL] [Abstract][Full Text] [Related]
72. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.
Di Stefano A; Sozio P; Cerasa LS; Iannitelli A
Curr Pharm Des; 2011; 17(32):3482-93. PubMed ID: 22074421
[TBL] [Abstract][Full Text] [Related]
73. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
Garbayo E; Ansorena E; Blanco-Prieto MJ
Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
[TBL] [Abstract][Full Text] [Related]
74. Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug.
Pflüger P; Pereira P; Loza MI; Brea J; Viña D; Kumar A; Fontenla JA
Eur J Pharmacol; 2021 Sep; 906():174276. PubMed ID: 34174267
[TBL] [Abstract][Full Text] [Related]
75. An MCASE approach to the search of a cure for Parkinson's Disease.
Klopman G; Sedykh A
BMC Pharmacol; 2002 Apr; 2():8. PubMed ID: 11926966
[TBL] [Abstract][Full Text] [Related]
76. Survey on general knowledge on Parkinson's disease in patients with Parkinson's disease and current clinical practice for Parkinson's disease among general neurologists from Southwest China.
Li J; Chen D; Song W; Chen K; Cao B; Huang R; Yang R; Shang H
Clin Neurol Neurosurg; 2014 Mar; 118():16-20. PubMed ID: 24529223
[TBL] [Abstract][Full Text] [Related]
77. [Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].
Cesaro P; Defebvre L
Rev Neurol (Paris); 2014 Apr; 170(4):237-46. PubMed ID: 24673985
[TBL] [Abstract][Full Text] [Related]
78. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.
Di Stefano A; Sozio P; Iannitelli A; Marianecci C; Santucci E; Carafa M
J Drug Target; 2006 Nov; 14(9):652-61. PubMed ID: 17090401
[TBL] [Abstract][Full Text] [Related]
79. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
[TBL] [Abstract][Full Text] [Related]
80. Pharmacological therapy of Parkinson's disease: current options and new avenues.
Simola N; Pinna A; Fenu S
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
